CSI Market
Sign In | Register

Intercept Pharmaceuticals inc (ICPT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ICPT quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Intercept Pharmaceuticals inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income221.82
Depreciation & amortization0.59
Amortization of Other Assets2.61
Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.60
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation21.89
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt91.78
Revaluation Of Warrants-
Impairment Of Bonds-
Gain Loss On Disposition Of Property-
Investment Income Amortization Of Premium-
Gain Loss On Termination Of Lease-1.10
Realized Gain Loss On Marketable Securities Operating Activities-
Noncash Operating Lease Cost1.67
Investment Income Net Amortization Of Discount And Premium-0.63
Increase Decrease In Operating Lease Liability-1.72
Income taxes0.00
Gain (Loss) on Investments, Excluding Other than Temporary Impairments0.00
Increase (Decrease) in Accounts Receivable1.48
Increase (Decrease) in Accounts Payable and Accrued Liabilities23.29
Increase (Decrease) in Interest Payable, Net-5.07
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.04
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-787.68
Discontinued operations403.64
Net Cash flow from Operating Activities-26.78
Investing Activities
Capital Expenditures-0.57
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities451.92
Payments to Acquire Available-for-sale Securities, Debt-552.74
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations363.23
Net Cash Flow from Investing Activities261.85
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.04
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.68
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding3.27
Other financing activities net0.00
Other net-3.83
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Convertible Promissory Notes Payable-
Payments For Capped Call Transactions And Associated Costs-
Payments For Repurchase Of Convertible Senior Notes-268.41
Proceeds From Terminations Of Capped Call Options-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-267.32
Effect of exchange rate on cash flow-6.30
Discontinued operations0.00
Free Cash Flow-27.35
Total Cash Flow-38.55
4 historic quarters locked

Sign in to unlock the full Intercept Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Intercept Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-017790

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License